Keywords: GlaxoSmithKline, XenoPort, Horizant, Restless legs syndrome, Merck & Co, vivriviroc, HIV, Research, FDA

GlaxoSmithKline/XenoPort get negative response from USA’s FDA for Horizant; Merck & Co won’t file for vicriviroc now

Article | 18 February 2010

Print This

UK drugs giant GlaxoSmithKline and partner XenoPort have received a negative response from the US Food and Drug Administration regarding ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in